Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000567916 | SCV000668977 | likely benign | Hereditary cancer-predisposing syndrome | 2017-09-07 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000781174 | SCV000919053 | likely benign | not specified | 2019-08-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001443618 | SCV001646598 | likely benign | Familial cancer of breast; Fanconi anemia complementation group J | 2025-01-08 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV004791589 | SCV005406653 | benign | Familial cancer of breast | 2024-08-30 | criteria provided, single submitter | clinical testing | This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. |
Gene |
RCV004797836 | SCV005420020 | uncertain significance | not provided | 2024-05-28 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this variant does not alter splicing; Has not been previously published as pathogenic or benign to our knowledge |